332 related articles for article (PubMed ID: 11308991)
1. Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours.
Kolomecki K; Stepien H; Bartos M; Kuzdak K
Endocr Regul; 2001 Mar; 35(1):9-16. PubMed ID: 11308991
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of MMP-1, MMP-8, MMP-9 serum levels in patients with adrenal tumors prior to and after surgery.
Kołomecki K; Stepień H; Bartos M; Narebski J
Neoplasma; 2001; 48(2):116-21. PubMed ID: 11478691
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor and basic fibroblast growth factor evaluation in blood serum of patients with hormonally active and inactive adrenal gland tumours.
Kołomecki K; Stepień H; Narebski JM
Cytobios; 2000; 101(396):55-64. PubMed ID: 10697745
[TBL] [Abstract][Full Text] [Related]
4. Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in the serum of patients with benign and malignant thyroid tumours treated surgically.
Pasieka Z; Stepien H; Czyz W; Pomorski L; Kuzdak K
Endocr Regul; 2004 Jun; 38(2):57-63. PubMed ID: 15497929
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
7. Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis.
Tamura M; Ohta Y
Cancer; 2003 Sep; 98(6):1217-22. PubMed ID: 12973845
[TBL] [Abstract][Full Text] [Related]
8. Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer.
Eroğlu A; Demirci S; Ayyildiz A; Kocaoğlu H; Akbulut H; Akgül H; Elhan HA
Br J Cancer; 1999 Jul; 80(10):1630-4. PubMed ID: 10408410
[TBL] [Abstract][Full Text] [Related]
9. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma.
Pennanen H; Kuittinen O; Turpeenniemi-Hujanen T
Eur J Haematol; 2008 Jan; 80(1):46-54. PubMed ID: 18028436
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors].
Peng XP; Li JD; Li MD; Ye XM; Yan WC
Ai Zheng; 2002 Feb; 21(2):181-5. PubMed ID: 12479072
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma.
Yoshino Y; Kageshita T; Nakajima M; Funakubo M; Ihn H
J Dermatol; 2008 Apr; 35(4):206-14. PubMed ID: 18419677
[TBL] [Abstract][Full Text] [Related]
12. [Significance of vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma].
Zhao J; Hu J; Cai J
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):389-92. PubMed ID: 11810769
[TBL] [Abstract][Full Text] [Related]
13. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
Quaranta M; Daniele A; Coviello M; Venneri MT; Abbate I; Caringella ME; Di Tardo S; Divella R; Trerotoli P; Di Gennaro M; Schittulli F; Fransvea E; Giannelli G
Anticancer Res; 2007; 27(5B):3593-600. PubMed ID: 17972522
[TBL] [Abstract][Full Text] [Related]
14. [Transforming growth factor beta, metalloproteinase 2 and its tissue inhibitor 2 in the serum from patients with early and late boreliosis].
Pancewicz SA; Izycka A; Klibingat M; Zajkowska JM; Swierzbińska-Pijanowska R; Kondrusik M; Grygorczuk SS; Izycki T; Hermanowska-Szpakowicz T
Pol Merkur Lekarski; 2008 Dec; 25(150):495-9. PubMed ID: 19205380
[TBL] [Abstract][Full Text] [Related]
15. The usefulness of determining the serum concentrations of vascular endothelial growth factor (VEGF) and its soluble receptor type 2 (sVEGF-2) in the differential diagnosis of adrenal incidentalomas.
Foltyn W; Strzelczyk J; Marek B; Kajdaniuk D; Siemińska L; Rosiek V; Kos-Kudła B
Endokrynol Pol; 2012; 63(1):22-8. PubMed ID: 22378094
[TBL] [Abstract][Full Text] [Related]
16. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
17. Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with oesophageal cancer.
McDonnell CO; Harmey JH; Bouchier-Hayes DJ; Walsh TN
Br J Surg; 2001 Aug; 88(8):1105-9. PubMed ID: 11488797
[TBL] [Abstract][Full Text] [Related]
18. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma.
Zhao J; Hu J; Cai J; Yang X; Yang Z
Chin Med J (Engl); 2003 May; 116(5):772-6. PubMed ID: 12875699
[TBL] [Abstract][Full Text] [Related]
20. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
